Browse molecules

The MMP-13 inhibitor’s prompt delivery, along with the collaborative expertise and exceptional support from opnMe, significantly accelerated my preclinical trial work, enhancing both the research speed of my PhD thesis and the quality of my publications.

Using opnMe's MMP-13 inhibitor, I was able to advance my pre-clinical research on protecting cartilage from progressive degeneration.

Through interactions with the SGC, we received a well-characterized donated chemical library, including BI-653048, with the generous support of opnMe. This was invaluable to our project, enabling extensive in vitro studies and crucial in vivo experiments. Without opnMe’s support, this would have been very difficult. We are truly grateful!

The opnMe innovation portal has been an invaluable resource in my scientific work. Its easy-to-use platform, comprehensive data, and support for collaboration provide great benefits, making it a valuable tool for any scientist looking to advance their research.

opnMe provided valuable resources that enabled my research in PROTAC delivery. The platform offered easy access to high-quality compounds, and their team was both cooperative and highly responsive.

From the generous support of opnMe, we were able to use an expensive compound, BI-653048, for free! This made critical experiments in cell lines and patient-derived xenografts possible. The process of ordering and receiving compounds was seamless and easy and I highly encourage more scientists to engage in open science.  

opnMe compounds deepened my understanding of cancer cell spreading, illuminating crucial molecular mechanisms. Grateful for their contribution in advancing my research.

opnMe has been an invaluable resource for our research and outputs, providing quick access to a Syk inhibitor with a seamless application process. I fully endorse the opnMe platform as a trusted means of advancing scientific discovery, and highly advise other scientists to consider using it.

I tested BI-9740, obtained for free in my experiments. This significantly advanced my research in anti-proteolytic therapy upstream of pro-inflammatory neutrophil serine proteases by blocking their maturating enzyme, cathepsin C. Their support has been crucial.

I found the opnMe team easy to work with, helpful and open in our discussions. Our request for one of their compounds was quickly acted upon and dispatched to us with little difficulty. And we are based in Australia. I am looking forward to continuing our connection as our research develops.